Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix Inc. was a biopharmaceutical company whose news centered on oncology drug development, regulatory interactions, governance actions, and capital-structure disclosures before its acquisition by Jazz Pharmaceuticals in April 2025. The company’s most advanced program was dordaviprone, also known as ONC201, in development for H3 K27M-mutant glioma, and its pipeline also included ONC206 research evaluating safety and pharmacokinetics.
Recurring Chimerix updates included FDA review milestones, clinical-development disclosures, operating and financial results, material agreements, and equity-compensation actions such as inducement grants under Nasdaq Listing Rule 5635(c)(4).
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.